記住我
High-impact catalysts upcoming in the fourth quarter of 2022 include the US approval decisions on teplizumab for type 1 diabetes, sparsentan for IgA nephropathy (IgAN) and adagrasib for non-small-cell lung cancer (NSCLC).
Competing InterestsThe author declares no competing interests.
留言 (0)